Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
 |
Results for 'Gene Therapy' |
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
|
Gene Therapy Technologies, Markets and Companies |
March 2010 | £3020 | 100 % |
|
Gene Therapy Worldwide Market Challenges & Opportunities |
November 2009 | £2010 | 100 % |
|
Gene Therapy in Oncology Drug Pipeline Update 2010 |
January 2010 | £1365 | 97 % |
|
Gene Therapy: Industry Background Report List of Companies |
October 2005 | £345 | 96 % |
|
Gene Amplification Technologies Trends & Opportunities Worldwide |
November 2009 | £2010 | 38 % |
|
Gene Express, Inc. Product Pipeline Analysis |
August 2008 | £505 | 35 % |
|
The Endometrium: Molecular, Cellular and Clinical Perspectives 2nd edition |
December 2007 | £280 | 34.3 % |
|
Multiple Myeloma |
October 2007 | £105 | 29.05 % |
|
Biotechnology in Australia IBISWorld Industry Report |
April 2009 | £395 | 28 % |
|
RNA therapy: the next big thing after monoclonal antibodies? |
October 2008 | £2685 | 27.65 % |
|
Global Biotechnology IBISWorld Industry Report |
September 2009 | £505 | 26.5 % |
|
Stakeholder Opinions Novel Therapeutic Approaches in Cardiovascular Medicine - Lack of Market Prospects for Biologics Expose An Opportunity for Cell and Gene Therapies |
July 2008 | £2550 | 25.55 % |
|
Molecular Diagnostics A World Market Review |
November 2009 | £2010 | 25 % |
|
Cell Therapy Technologies, Markets and Companies |
March 2010 | £3355 | 25 % |
|
Biotechnology in the US IBISWorld Industry Report |
March 2009 | £435 | 24.5 % |
|
Understanding Genomics and Global Health Impacts The Study of Disease at the Cellular and Molecular Level |
January 2009 | £400 | 24.5 % |
|
Pharmaceutical Biotechnology: Fundamentals and Applications Third Edition |
October 2007 | £115 | 22.4 % |
|
Stakeholder Opinions: Cystic Fibrosis |
March 2006 | £1475 | 22.4 % |
|
Pharmaceutical Biotechnology Drug Discovery and Clinical Applications |
February 2004 | £115 | 21.7 % |
|
Top Companies and Products in the RNA/DNA Therapy Products Market Forecasts: The Challenge Of Turning Technology Into Therapy |
July 2007 | £1999 | 21.35 % |
|
PARP Inhibitors Competitor Analysis |
April 2009 | £91 | 20.5 % |
|
Biotechnology and Biopharmaceuticals Transforming Proteins and Genes into Drugs |
July 2003 | £55.95 | 19.95 % |
|
Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: A Guidebook of Registration Application for Imported Biological Products China Pharmaceutical Guidebook Series (4) (3rd edition) |
October 2009 | £505 | 19.95 % |
|
Textbook of Interventional Cardiovascular Pharmacology |
April 2007 | £140 | 19.6 % |
|
Cancer Therapeutics Markets |
May 2008 | £2280 | 18.55 % |
|
Understanding Pharmacogenomics Maximum Efficacy with Minimal Adverse Effects |
January 2009 | £335 | 18.5 % |
|
Cancer Drug Resistance 2008 |
September 2008 | £1675 | 18 % |
|
Melanoma - Targeted Therapeutics |
July 2007 | £1420 | 17.85 % |
|
Drug Delivery: Principles and Applications |
May 2005 | £61.5 | 17.5 % |
|
Osmetech plc Product Pipeline Analysis |
August 2008 | £505 | 17.15 % |
|
Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment |
March 2009 | £200 | 17.15 % |
|
Cardiovascular Drug Delivery Technologies, Markets and Companies |
March 2010 | £1680 | 16.8 % |
|
Currently Druggable in Melanoma A Drug Target Competitive Analysis |
October 2008 | £1780 | 16.8 % |
|
Currently Druggable in Breast Cancer A Drug Target Competitive Analysis |
August 2008 | £1780 | 16.45 % |
|
Currently Druggable in Prostate Cancer A Drug Target Competitive Analysis |
September 2008 | £1780 | 16.1 % |
|
Drug Targets for Breast Cancer |
January 2006 | £1095 | 16.1 % |
|
Islet Transplantation and Beta, Cell Replacement therapy |
April 2007 | £145 | 15.75 % |
|
Currently Druggable in Colorectal Cancer A Drug Target Competitive Analysis |
December 2008 | £1780 | 15.75 % |
|
Dircetory of Clinical Research Companies in India |
January 2008 | £600 | 15.5 % |
|
Bcr-Abl Kinase Inhibitors Competitor Analysis |
July 2009 | £180 | 15.5 % |
|
Bioms Medical Corp Premium Company Profile |
April 2008 | £180 | 15.5 % |
|
Carotid Atherosclerotic Disease: Pathologic Basis for Treatment |
April 2007 | £125 | 15.4 % |
|
Apoptotic Therapeutics in Oncology - Where to Commercialize? |
November 2009 | £2235 | 15.05 % |
|
Cellular Therapy in Oncology Drug Pipeline Update 2010 |
January 2010 | £910 | 15 % |
|
Tercica Inc Premium Company Profile |
December 2007 | £180 | 15 % |
|
Orthopedic Biomaterials, The World Market, 2nd Edition |
September 2007 | £2350 | 14.35 % |
|
China Asthma Drug Market Report The Chinese Asthma Drug Drug Utilization |
May 2009 | £3020 | 14.35 % |
|
Drug Delivery Technology: Revolutionizing Cardiovascular Therapies |
July 2007 | £945 | 14.35 % |
|
Biotechnological Innovations In The Pharmaceutical Industry in Poland 2009 Development forecasts for biotechnology sector for 2009-2011 |
August 2009 | £1825 | 14 % |
|
Systems Biology A Disruptive Technology |
May 2008 | £755 | 14 % |
|
Diagnostics and Therapeutics for Genetic Diseases |
April 2006 | £3255 | 14 % |
|
Orthopedic Biomaterials, The World Market 2nd Edition |
September 2007 | £2350 | 14 % |
|
Gen-Probe Incorporated Product Pipeline Analysis |
August 2008 | £505 | 14 % |
|
Drug Delivery in Central Nervous System Diseases Technologies,Markets and Companies |
October 2009 | £1680 | 13.65 % |
|
Stakeholder Opinions: Pancreatic Cancer - Gemzar dominance will continue among high levels of persistent unmet needs Healthcare |
March 2009 | £1340 | 13.65 % |
|
Drug Delivery to CNS |
March 2010 | £1880 | 13.65 % |
|
Triple Analysis: Melanoma Therapeutics, Antibodies and Vaccines in Oncology |
August 2006 | £3145 | 13.65 % |
|
Drug Delivery to Central Nervous System Diseases Technologies, Markets and Companies |
February 2010 | £1880 | 13.65 % |
|
Wound Care Markets, 3rd. Edition, Vol. I Skin Ulcers |
July 2007 | £2010 | 13.3 % |
|
Nanobiotechnologies Applications, Markets and Companies |
May 2009 | £2685 | 13 % |
|
RNA Interference Therapy in Oncology Drug Pipeline Update 2010 |
January 2010 | £910 | 13 % |
|
Drug Delivery Technology: Revolutionizing Diabetes Treatment |
September 2007 | £945 | 12.95 % |
|
Drug Delivery Technology Revolutionizing Diabetes Treatment |
September 2007 | £945 | 12.95 % |
|
Analysis of the Pharmaceutical Market to 2012 - Segmented by Drug Target Family Sales & Marketing |
October 2007 | £2550 | 12.95 % |
|
The Future of Targeted Therapeutics Key Technologies, New Therapy Area Applications and Leading Players |
March 2008 | £1995 | 12.95 % |
|
Molecular Diagnostics: a primer on an emerging sector |
November 2008 | £2685 | 12.6 % |
|
Animal Biotechnology Technologies, Markets and Companies |
March 2010 | £1680 | 12.6 % |
|
Stakeholder Opinions: Restless Legs Syndrome Novel drugs to prosper as lifecycle management strategies fail |
November 2008 | £2685 | 12.6 % |
|
Stem Cell-Based Therapeutic Delivery Challenges & Opportunities |
December 2008 | £945 | 12.6 % |
|
Wound Care Markets, 4th. Edition, Vol. I: Skin Ulcers |
March 2003 | £2010 | 12.6 % |
|
Cytokine Therapy in Oncology Drug Pipeline Update 2010 |
January 2010 | £910 | 12.5 % |
|
Pipeline Insight: Breast Cancer Recent approvals increase pressure on pipeline candidates |
April 2008 | £4025 | 12.25 % |
|
Delivering RNAi-Based Therapeutics & Diagnostics Challenges & Opportunities |
July 2009 | £945 | 12.25 % |
|
Pipeline Insight: Migraine Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries |
December 2006 | £4025 | 12.25 % |
|
Cancer Cell Therapy Markets |
March 2008 | £2280 | 12.25 % |
|
Cell Therapy Markets |
July 2007 | £2280 | 11.9 % |
|
Impact of Pharmacogenomics on Public Healthcare Policy Educating Patients, Payors and Healthcare Providers |
March 2008 | £1995 | 11.9 % |
|
Genetic Test Reagents Clinical Trial Analysis |
July 2009 | £670 | 11.9 % |
|
The Future of Monoclonal Antibodies Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis |
December 2009 | £2350 | 11.9 % |
|
US Coronary Stents Market: Revival of Drug Eluting Stents to Drive Growth |
May 2005 | £2350 | 11.9 % |
|
Pipeline Insight: Molecular Targeted Cancer Therapies Can anything else revolutionize the market? - Cancer |
October 2007 | £5100 | 11.9 % |
|
Triple Progress Analysis: Melanoma, Colorectal & Lung Cancer |
March 2006 | £3145 | 11.55 % |
|
Pharmaceutical Regulatory Affairs in The Eu & US |
January 2006 | £1095 | 11.55 % |
|
Protein Kinase Inhibitors in Oncology Drug Pipeline Update 2009 |
May 2007 | £1365 | 11.5 % |
|
Tumour Markers Clinical Trial Analysis |
July 2009 | £670 | 11.2 % |
|
Europe Coronary Stents Market: Revival of Drug Eluting Stents to Drive Growth |
May 2009 | £2350 | 11.2 % |
|
Drug Delivery in Cancer Technologies, Markets and Companies |
March 2010 | £2350 | 11.2 % |
|
China Senile Dementia Drug Market Report The Chinese Dementia Drug Utilization |
March 2009 | £5370 | 11.2 % |
|
Radiation Therapy in Oncology Drug Pipeline Update 2010 |
January 2010 | £1365 | 11 % |
|
Renal Cancer Drug Pipeline Update 2009 |
May 2007 | £1365 | 11 % |
|
Prostate Cancer Drug Pipeline Update 2009 |
May 2007 | £1365 | 11 % |
|
Colorectal Cancer Drug Pipeline Update 2009 |
January 2009 | £1365 | 11 % |
|
Stakeholder Opinions: Cystic Fibrosis - A pipeline full of hope Healthcare |
March 2009 | £1340 | 10.85 % |
|
Competitive Outlook on HCV What to Know & Expect in R&D and Business Development |
June 2004 | £910 | 10.85 % |
|
Disease Specific Test Reagents Clinical Trial Analysis |
July 2009 | £670 | 10.85 % |
|
Nitric Oxide Therapeutics, Markets and Companies |
March 2010 | £1880 | 10.85 % |
|
Stakeholder Opinions: Head and Neck Cancer Innovatives to Change the Face of Treatment |
November 2007 | £1345 | 10.85 % |
|
Modern Biopharmaceuticals Design, Development and Optimization, 4 Volumes |
September 2005 | £440 | 10.85 % |
|
RNAi Technologies, Markets and Companies |
March 2010 | £2350 | 10.85 % |
|
Antiviral Therapeutics Technologies, Markets and Companies |
March 2010 | £2145 | 10.85 % |
|
Outlook for RNAi, 2007 siRNA and miRNA in biology, diagnostics and therapeutics |
June 2007 | £1495 | 10.85 % |
|
Bladder Cancer Drug Pipeline Update 2009 |
January 2009 | £910 | 10.5 % |
|
Neurodegenerative Disease Drug Market Analysis and Forecasts 2007 |
June 2007 | £1999 | 10.5 % |
|
Burger's Medicinal Chemistry and Drug Discovery 6 Volume Set |
March 2003 | £1730 | 10.5 % |
|
Global Cardiovascular Drugs Market 2009-2024 |
June 2009 | £1499 | 10.5 % |
|
Epigenetics Technologies, Applications, and the Commercial Landscape |
February 2008 | £1260 | 10.5 % |
|
Ribonucleic Acid (RNA) Therapeutics Strong Potential to Address Unmet Needs in Pharma |
February 2010 | £2350 | 10.5 % |
|
Parkinson's Disease Drug Pipeline Analysis and Market Forecasts to 2015 |
December 2009 | £1340 | 10.5 % |
|
The Future of Biobanks Regulation, ethics, investment and the humanization of drug discovery |
March 2009 | £2025 | 10.5 % |
|
Renal Cancer Drug Pipeline Update 2010 |
January 2010 | £1365 | 10.5 % |
|
Protein Kinase Inhibitors in Oncology Drug Pipeline Update 2010 |
January 2010 | £1365 | 10.5 % |
|
Colorectal Cancer Drug Pipeline Update 2010 |
January 2010 | £1365 | 10.5 % |
|
Convergence of Biomarkers and Diagnostics, The Therapy Area Analyses, Key Products and Future Trends |
April 2008 | £1995 | 10.15 % |
|
Parkinson's Disease Market analysis and forecasts 2008-2012, 2017 & 2022 |
January 2008 | £1499 | 10.15 % |
|
Indian Biotechnology |
January 2008 | £600 | 10.15 % |
|
Pipeline And Commercial Insight: Parkinson's Disease Market To Grow As First Round Of Lifecycle Management Strategies Succeed |
September 2007 | £5100 | 10.15 % |
|
AMD Market Outlook to 2012 |
March 2007 | £1299 | 10.15 % |
|
Molecular Diagnostics in Cancer Testing |
December 2009 | £2280 | 10.15 % |
|
Personalized Medicine: Technologies and the Global Market |
July 2009 | £3255 | 10.15 % |
|
Stem Cell Therapies and Regenerative Medicine Current Applications and Future Possibilities |
December 2005 | £3255 | 10.15 % |
|
Neuroendocrine Tumors Drug Pipeline Update 2010 |
January 2010 | £910 | 10 % |
|
Prostate Cancer - A Therapeutic & Competitive Insight Pipeline Update 2010 |
January 2010 | £1365 | 10 % |
|
Siemens Medical Solutions Medical Device Company Intelligence Report |
February 2007 | £395 | 10 % |
|
Liver Cancer Drug Pipeline Update 2009 |
January 2009 | £910 | 10 % |
|
Cancer Therapeutics: The Worldwide Market The Worldwide Market , 2nd Editon |
February 2007 | £2680 | 9.8 % |
|
Opportunities in Stem Cell Research and Commercialization Technology advances, regulatory impact and key players |
April 2006 | £1495 | 9.8 % |
|
World Neurodegenerative Diseases Market 2009-2024 |
September 2009 | £1499 | 9.8 % |
|
Lymphoma Drug Development Strategies at Work |
June 2009 | £1780 | 9.8 % |
|
Wound Care Markets, 4th. Edition, Vol. III: Surgical and Trauma Wounds |
May 2009 | £1910 | 9.8 % |
|
Labeling and Linkage Agents for Immunoassays and Gene Probes |
April 2006 | £3255 | 9.8 % |
|
Worldwide Wound Care Markets: Total Coverage (Vol. I-III: Skin Ulcers, Burns, Surgical and Trauma Wounds), 4th Edition |
May 2009 | £3350 | 9.8 % |
|
Drug Delivery Technology: Revolutionizing CNS Therapies |
December 2007 | £945 | 9.8 % |
|
Cancer Vaccines Drug Pipeline Update 2009 |
January 2009 | £1365 | 9.5 % |
|
Liver Cancer Drug Pipeline Update 2010 |
January 2010 | £910 | 9.5 % |
|
Breast Cancer Drug Pipeline Update 2009 |
January 2009 | £1365 | 9.5 % |
|
Bladder Cancer Drug Pipeline Update 2010 |
January 2010 | £910 | 9.5 % |
|
Brain Cancer Drug Pipeline Update 2009 |
January 2009 | £1365 | 9.5 % |
|
Angiogenesis in Oncology Drug Pipeline Update 2009 |
January 2009 | £1365 | 9.5 % |
|
Leukemia Drug Pipeline Update 2009 |
January 2009 | £1365 | 9.5 % |
|
Ovarian Cancer Drug Pipeline Update 2009 |
January 2009 | £1365 | 9.5 % |
|
Pancreatic Cancer Drug Pipeline Update 2009 |
January 2009 | £1365 | 9.5 % |
|
Melanoma Drug Pipeline Update 2009 |
January 2009 | £1365 | 9.5 % |
|
Lymphoma Drug Pipeline Update 2009 |
January 2009 | £1365 | 9.5 % |
|
Head and Neck Cancer Drug Pipeline Update 2010 |
January 2010 | £1365 | 9.5 % |
|
Hematological Cancers Drug Pipeline Update 2009 |
January 2009 | £1820 | 9.5 % |
|
Peptides in Oncology Drug Pipeline Update 2010 |
January 2010 | £1365 | 9.5 % |
|
Competitive Outlook on Non-Antibody Based Cancer Vaccines |
August 2006 | £1780 | 9.45 % |
|
Competitive Outlook of Cancer Drug Development The Missing Handbook to New Product Planning and Portfolio Planning |
August 2009 | £2235 | 9.45 % |
|
Innovations in Cancer Novel Therapeutics, New Diagnostics and Future R&D Strategies |
February 2007 | £1495 | 9.45 % |
|
Triple Analysis: Apoptosis Agents, Antibodies and Vaccines in Oncology |
December 2006 | £3145 | 9.45 % |
|
Obesity Drug Discoveries: what the future holds + Obesity Tracker |
August 2007 | £1425 | 9.45 % |
|
Innovation in Drug Delivery The future of nanotechnology and non-invasive protein delivery |
November 2006 | £1495 | 9.45 % |
|
Stakeholder Opinions: Acute Leukemias Persistent unmet needs confer significant commercial opportunity |
April 2006 | £1455 | 9.45 % |
|
Obesity Drug Discoveries: what the future holds |
August 2007 | £1425 | 9.45 % |
|
Pipeline Insight: HIV Extending treatment options |
September 2006 | £4025 | 9.1 % |
|
Pipeline Insight: Non-insulin antidiabetics Incretin mimetics leaders in a diverse pipeline |
May 2008 | £4025 | 9.1 % |
|
World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 |
July 2009 | £1499 | 9.1 % |
|
Biomarkers in Drug Discovery Optimizing Drug Discovery Timeline and Costs |
February 2010 | £2350 | 9.1 % |
|
Leukemia A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking |
April 2009 | £1780 | 9.1 % |
|
Transdermal Drug Delivery Technologies, Markets and Companies |
March 2010 | £1880 | 9.1 % |
|
Pain Therapeutics Drugs, Markets and Companies |
March 2010 | £2350 | 9.1 % |
|
Pharmaceutical Regulatory Affairs in the EU and US |
December 2006 | £1095 | 9.1 % |
|
Organ Transplant Immunosuppressive Markets |
January 2008 | £2350 | 9.1 % |
|
Stakeholder Opinions: Melanoma Lucrative commercial opportunities persist |
December 2006 | £1340 | 9.1 % |
|
Melanoma Drug Pipeline Update 2010 |
January 2010 | £1365 | 9 % |
|
Antibodies in Oncology Pipeline Update 2010 |
January 2010 | £1365 | 9 % |
|
Ovarian Cancer Drug Pipeline Update 2010 |
January 2010 | £1365 | 9 % |
|
Vascular Targeting and Anti-angiogenesis in Oncology Pipeline Update 2010 |
January 2010 | £1365 | 9 % |
|
Brain Cancer Drug Pipeline Update 2010 |
January 2010 | £1365 | 9 % |
|
Lymphoma Drug Pipeline Update 2010 |
January 2010 | £1365 | 9 % |
|
Cancer Vaccines Drug Pipeline Update 2010 |
January 2010 | £1365 | 9 % |
|
Hematological Cancers Drug Pipeline Update 2010 |
January 2010 | £1820 | 9 % |
|
Breast Cancer Drug Pipeline Update 2010 |
January 2010 | £1365 | 9 % |
|
Immunotherapy in Oncology Drug Pipeline Update 2010 |
January 2010 | £2235 | 9 % |
|
Leukemia Drug Pipeline Update 2010 |
January 2010 | £1365 | 9 % |
|
Pancreatic Cancer Drug Pipeline Update 2010 |
January 2010 | £1365 | 9 % |
|
Lung Cancer Drug Pipeline Update 2009 |
January 2009 | £1365 | 9 % |
|
Apoptosis in Oncology Pipeline Update 2010 |
January 2010 | £1365 | 9 % |
|
India in Vitro Diagnostics Investment Opportunities Analysis and Forecasts to 2015 |
April 2009 | £1680 | 8.75 % |
|
Stakeholder Opinions: Primary Brain Cancer Temozolomide Turns Heads |
July 2007 | £1340 | 8.75 % |
|
World market for cancer vaccines 2007-2012 |
January 2007 | £1999 | 8.75 % |
|
Market for Advanced Wound Care Technology; The |
January 2007 | £3255 | 8.75 % |
|
Personalized Medicine Scientific & Commercial Aspects |
March 2010 | £2685 | 8.75 % |
|
Top 7 Cancer Indications Therapeutic & Competitive Insights |
January 2007 | £6335 | 8.75 % |
|
Pipeline Insight: Heart failure Week pipeline dominated by new indications and add-on diuretics |
August 2007 | £4025 | 8.75 % |
|
Lung Cancer Drug Pipeline Update 2010 |
January 2010 | £1365 | 8.5 % |
|
The Deployment of Antibody Technologies for the Advancement of Cancer Therapeutics |
April 2008 | £2050 | 8.4 % |
|
Neuroprotection Drugs, Markets and Companies |
March 2010 | £3020 | 8.4 % |
|
Wound Care, 3rd Edition, Vol. II: Burns |
September 2007 | £2010 | 8.4 % |
|
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC |
July 2007 | £2515 | 8.4 % |
|
United Kingdom in Vitro Diagnostics Investment Opportunities Analysis and Forecasts to 2015 |
April 2009 | £1680 | 8.4 % |
|
Molecular Diagnostics Markets |
September 2008 | £2280 | 8.05 % |
|
Emerging Technologies in Spinal Motion Preservation |
October 2006 | £1295 | 8.05 % |
|
Hepatitis C Virus and Therapeutics A Global Update of Market Trends & Opportunities |
November 2009 | £2010 | 8.05 % |
|
Innovations in CNS Novel therapeutics and future R&D strategies |
January 2007 | £1495 | 8.05 % |
|
Wound Care Markets, 4th. Edition, Vol. II: Burns |
April 2004 | £2010 | 8.05 % |
|
Stem Cell Therapeutics Markets |
February 2002 | £1680 | 8.05 % |
|
RNA Interference Markets |
December 2008 | £2280 | 7.7 % |
|
Enzymes US industry forecasts to 2010 & 2015 |
July 2006 | £2885 | 7.7 % |
|
Personalized Medicine |
August 2007 | £1340 | 7.7 % |
|
Nanotechnology in Life Science Applications |
October 2005 | £3255 | 7.7 % |
|
Pipeline Insight: Parkinson's Disease and Restless Legs Syndrome Reformulations set to drive near-term growth |
August 2006 | £5835 | 7.7 % |
|
Targeted Therapies in Oncology A World Review |
December 2006 | £4510 | 7.7 % |
|
Innovations In Epigenetics Advances in Technologies, Diagnostics & Therapeutics |
November 2009 | £3835 | 7.7 % |
|
Alzheimer's disease New drugs, markets and companies |
December 2008 | £2015 | 7.7 % |
|
Bioinformatics Technical Status and Market Prospects |
August 2005 | £3255 | 7.7 % |
|
Disease Specific Markers Clinical Trial Analysis |
July 2009 | £670 | 7.7 % |
|
Biomarkers Technologies, Markets and Companies |
March 2010 | £3020 | 7.35 % |
|
A Practical Guide to Biopharmaceutical Manufacturing |
January 2006 | £1095 | 7.35 % |
|
Alzheimer's disease New Drugs, Markets and Companies |
October 2009 | £2015 | 7.35 % |
|
Bladder Cancer Therapeutics |
February 2010 | £2650 | 7.35 % |
|
Alzheimer's Disease New Drugs, Markets and Companies |
February 2010 | £2145 | 7.35 % |
|
Alzheimer Disease New Drugs, Markets and Companies |
May 2009 | £1880 | 7.35 % |
|
Alzheimer's Disease New Drugs, Markets and Companies |
October 2009 | £2015 | 7.35 % |
|
Cystic Fibrosis Drug Pipeline Analysis and Market Forecasts to 2015 |
December 2009 | £1340 | 7.35 % |
|
Pipeline Insight: Osteoarthritis The Wait for a DMOAD Continues |
November 2006 | £4025 | 7.35 % |
|
Alzheimer's disease |
March 2010 | £2145 | 7.35 % |
|
Multiple Myeloma Therapeutics US Market Trends & Analysis |
November 2009 | £2010 | 7 % |
|
Nanobiotechnology Applications, Markets and Companies |
March 2010 | £3020 | 7 % |
|
Regenerative Medicines: Bone and Joint Applications |
October 2009 | £3255 | 7 % |
|
United States in Vitro Diagnostics Investment Opportunities Analysis and Forecasts to 2015 |
April 2009 | £1680 | 7 % |
|
Preclinical Cancer Therapeutics 2007 Decoding Next Generation Drug Targets for Market Success |
December 2006 | £1600 | 7 % |
|
Cancer Biomarkers Enhancing diagnostic, therapeutic and developmental strategies |
May 2006 | £1475 | 7 % |
|
Triple Analysis: Protein Kinase Inhibitors, Antibodies and Vaccines in Oncology |
August 2006 | £3145 | 7 % |
|
Diabetes Drug Pipeline Competitor Analysis |
November 2008 | £1095 | 7 % |
|
Drug Delivery Technologies: Players, products & prospects to 2015 |
November 2007 | £1795 | 7 % |
|
Triple Progress Analysis: Lymphoma Therapeutics, Protein Kinase Inhibitors & Therapeutic Antibodies |
May 2006 | £3145 | 7 % |
|
Stakeholder Insight: Atherosclerosis HDL, ApoA-I, Carotid MRI and 64-slice CT offer opportunities for future treatment |
December 2006 | £5370 | 6.65 % |
|
Pipeline Insight: Cancer Overview Increasing Diversity Offers Both High Risk And Reward |
September 2007 | £5100 | 6.65 % |
|
Ophthalmic Pharmaceuticals, Market Analysis, Forecasts and Dynamics 2009-2023 |
January 2009 | £1499 | 6.65 % |
|
Proteomics Technologies, Markets and Companies |
March 2010 | £3020 | 6.65 % |
|
Drug Delivery Systems US Market Outlook, Advances for Pharma, Biotech & Medical Devices |
September 2006 | £1540 | 6.3 % |
|
What's Hot in Cancer Drug R&D? |
July 2006 | £295 | 6.3 % |
|
Molecular Diagnostics Technologies, Markets and Companies |
March 2010 | £3355 | 6.3 % |
|
Innovative Drug R&D in China |
October 2009 | £1945 | 6 % |
|
GSK's Cervarix A Future Blockbuster of 2007 |
March 2007 | £1999 | 5.95 % |
|
Epigenetics |
February 2010 | £3020 | 5.95 % |
|
Companion Diagnostics in Personalized Medicine and Cancer Therapy |
April 2008 | £2280 | 5.95 % |
|
Growth Factors (Blood and Tissue) A World Report |
November 2009 | £2010 | 5.95 % |
|
Coagulation Factors 2009 Target Pipeline and Corporate Benchmark Analysis |
August 2009 | £2235 | 5.95 % |
|
Drug-Device Combinations The Global Market |
January 2010 | £3255 | 5.6 % |
|
Pediatric Health Care Products and Services |
March 2009 | £3255 | 5.6 % |
|
Pipeline Insight: Hematological Malignancies Companies target niche indications to facilitate market entry |
April 2009 | £4025 | 5.6 % |
|
Nanomedicine |
July 2009 | £2650 | 5.6 % |
|
Innovations in Cardiovascular Disease Management Latest surgical procedures, drugs and medical devices |
September 2007 | £1495 | 5.6 % |
|
Biomedical Imaging From Drug Target Discovery to Medical Diagnostics |
December 2008 | £2515 | 5.6 % |
|
Chemotherapy Market Insights, 2006-2016 A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities |
April 2006 | £1900 | 5.6 % |
|
Pharmacogenomics: New Technologies In the Development of Personalized Therapies |
August 2005 | £3255 | 5.6 % |
|
ASCO 2009: Significant Developments in Context |
July 2009 | £595 | 5.25 % |
|
Stakeholder Insight: Supportive Care in Cancer Treatment Some first-generation products proving difficult to dislodge |
October 2006 | £5370 | 5.25 % |
|
Epigenomics Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics |
March 2007 | £3255 | 5.25 % |
|
DNA Diagnostics: Technologies and Global Markets |
January 2008 | £3255 | 4.9 % |
|
Alzheimer's and Parkinson's Diseases A Global Update of Market Trends & Opportunities |
November 2009 | £2010 | 4.9 % |
|
Alzheimer's and Parkinson's Diseases A Global Update of Market Trends & Opportunities |
November 2009 | £2010 | 4.9 % |
|
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Leukemias and Lymphomas |
June 2007 | £2515 | 4.55 % |
|
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer |
June 2007 | £2515 | 4.55 % |
|
Therapeutics for Memory and Cognition Disorders |
April 2009 | £3255 | 4.55 % |
|
Clinical Trials Business; The |
August 2006 | £3255 | 4.55 % |
|
Therapeutics for Inflammatory Diseases Current Challenges and Future Market |
March 2006 | £3255 | 4.2 % |
|
Blood The Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products |
September 2006 | £2615 | 4.2 % |
|
Drug Discovery Technologies A Global Update of Market Trends & Opportunities |
November 2009 | £2010 | 4.2 % |
|
Human Vaccines Global Market Opportunities |
November 2009 | £2010 | 4.2 % |
|
The World Dermatological Market Outlook 2010-2024 |
November 2009 | £1499 | 4.2 % |
|
Companion Biomarkers in Drug Development |
April 2009 | £2280 | 3.85 % |
|
Veterinary Health Markets |
December 2008 | £2280 | 3.85 % |
|
In Vitro Diagnostics Market Report & Analysis 2008-2023 |
June 2008 | £1499 | 3.5 % |
|
Orthopedic Instrumentation A Global Market Perspective |
November 2009 | £2315 | 3.15 % |
|
Spinal Surgery |
July 2009 | £2650 | 2.8 % |
|
PAREXEL's Bio/Pharma R&D Statistical Sourcebook 2009 / 2010 |
June 2009 | £285 | 2.8 % |
|
Parexel's Pharmaceutical R&D Statistical Sourcebook 2007/2008 |
May 2007 | £285 | 2.45 % |
|
The Executive Guide to Molecular Imaging |
July 2007 | £595 | 2.45 % |
|
Nanobiotechnology |
February 2010 | £2985 | 2.45 % |
|
Live-Licensing & In-life Testing R&D Processes and Regulation for New Drugs, 2008-2020 |
January 2008 | £1499 | 2.45 % |
|
IND: Submissions |
February 2009 | £200 | 2.1 % |
